Published in Medical Letter on the CDC and FDA, July 5th, 2009
"Based on the trial data to date, we are confident that the LibiGel Cardiovascular and Breast Cancer Safety Study should continue to enroll new subjects and maintain treatment of those subjects already randomized to therapy. At this point, we feel...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.